Supratentorial primitive neuroectodermal tumors: a Canadian pediatric brain tumor consortium report - PubMed (original) (raw)

Multicenter Study

doi: 10.1007/s11060-007-9440-1. Epub 2007 Jul 10.

Daniel L Keene, Lucie Lafay-Cousin, Paul Steinbok, Lillian Sung, Anne-Sophie Carret, Bruce Crooks, Douglas Strother, Beverly Wilson, Isaac Odame, David D Eisenstat, Chris Mpofu, Shayna Zelcer, Annie Huang, Eric Bouffet

Affiliations

• PMID: 17619825
• DOI: 10.1007/s11060-007-9440-1

Multicenter Study

Supratentorial primitive neuroectodermal tumors: a Canadian pediatric brain tumor consortium report

Donna L Johnston et al. J Neurooncol. 2008 Jan.

Abstract

Introduction: Supratentorial primitive neuroectodermal tumors (SPNET) are rare tumors accounting for only 2.5% of childhood brain tumors. The purpose of this study was to describe the range of treatment regimens used to treat pediatric SPNET in Canada and to identify prognostic factors for overall survival in this population.

Methods: This study was a retrospective clinical analysis of SPNET patients treated over the last 10 years in Canada. A questionnaire was developed and distributed to all institutions in Canada who treat pediatric patients. Data were collected for patients <19 years of age who were diagnosed and treated for SPNET between 1995 and 2005.

Results: Data were obtained for 48 eligible patients. The stages of patients for whom complete data were provided were 80, 3, and 16% for metastatic stage M0, M1, and M2/3, respectively. The best responses to therapy included complete response in 44%, partial response in 8%, still on therapy in 2%, progressive disease in 31%, toxic death in 2%, and no therapy given in 12%. The 4-year survival was 37.7 +/- 7.6%. The factors associated with an increase in survival were the use of radiation therapy and chemotherapy, and age >2 years. Overall survival was not affected by metastatic disease at diagnosis, tumor site, or degree of initial resection.

Conclusions: Survival is poor in SPNET patients but highest in those who received chemotherapy and radiation therapy. Further studies are needed to improve the survival of these patients.

PubMed Disclaimer

Similar articles

• Outcome and prognostic factors for children with supratentorial primitive neuroectodermal tumors treated with carboplatin during radiotherapy: a report from the Children's Oncology Group.
  Jakacki RI, Burger PC, Kocak M, Boyett JM, Goldwein J, Mehta M, Packer RJ, Tarbell NJ, Pollack IF. Jakacki RI, et al. Pediatr Blood Cancer. 2015 May;62(5):776-83. doi: 10.1002/pbc.25405. Epub 2015 Feb 19. Pediatr Blood Cancer. 2015. PMID: 25704363 Free PMC article. Clinical Trial.
• Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experience.
  Fangusaro J, Finlay J, Sposto R, Ji L, Saly M, Zacharoulis S, Asgharzadeh S, Abromowitch M, Olshefski R, Halpern S, Dubowy R, Comito M, Diez B, Kellie S, Hukin J, Rosenblum M, Dunkel I, Miller DC, Allen J, Gardner S. Fangusaro J, et al. Pediatr Blood Cancer. 2008 Feb;50(2):312-8. doi: 10.1002/pbc.21307. Pediatr Blood Cancer. 2008. PMID: 17668858 Clinical Trial.
• Non-pineal supratentorial primitive neuro-ectodermal tumors (sPNET) in teenagers and young adults: Time to reconsider cisplatin based chemotherapy after cranio-spinal irradiation?
  Biswas S, Burke A, Cherian S, Williams D, Nicholson J, Horan G, Jefferies S, Williams M, Earl HM, Burnet NG, Hatcher H. Biswas S, et al. Pediatr Blood Cancer. 2009 Jul;52(7):796-803. doi: 10.1002/pbc.21899. Pediatr Blood Cancer. 2009. PMID: 19202566 Clinical Trial.
• Treatment outcome and patterns of failure in patients of non-pineal supratentorial primitive neuroectodermal tumor: review of literature and clinical experience form a regional cancer center in north India.
  Biswas A, Mallick S, Purkait S, Roy S, Sarkar C, Bakhshi S, Singh M, Julka PK, Rath GK. Biswas A, et al. Acta Neurochir (Wien). 2015 Jul;157(7):1251-66. doi: 10.1007/s00701-015-2444-2. Epub 2015 May 20. Acta Neurochir (Wien). 2015. PMID: 25990846 Review.
• Pineal and nonpineal supratentorial primitive neuroectodermal tumors.
  Jakacki RI. Jakacki RI. Childs Nerv Syst. 1999 Oct;15(10):586-91. doi: 10.1007/s003810050547. Childs Nerv Syst. 1999. PMID: 10550590 Review.

Cited by

• MYCN amplification predicts poor outcome for patients with supratentorial primitive neuroectodermal tumors of the central nervous system.
  Gessi M, von Bueren A, Treszl A, zur Mühlen A, Hartmann W, Warmuth-Metz M, Rutkowski S, Pietsch T. Gessi M, et al. Neuro Oncol. 2014 Jul;16(7):924-32. doi: 10.1093/neuonc/not302. Neuro Oncol. 2014. PMID: 24470553 Free PMC article.
• Long-term safety of growth hormone replacement therapy after childhood medulloblastoma and PNET: it is time to set aside old concerns.
  Indini A, Schiavello E, Biassoni V, Bergamaschi L, Magni MC, Puma N, Chiaravalli S, Pallotti F, Seregni E, Diletto B, Pecori E, Gandola L, Poggi G, Massimino M. Indini A, et al. J Neurooncol. 2017 Jan;131(2):349-357. doi: 10.1007/s11060-016-2306-7. Epub 2016 Oct 21. J Neurooncol. 2017. PMID: 27770281
• Outcome and prognostic factors for children with supratentorial primitive neuroectodermal tumors treated with carboplatin during radiotherapy: a report from the Children's Oncology Group.
  Jakacki RI, Burger PC, Kocak M, Boyett JM, Goldwein J, Mehta M, Packer RJ, Tarbell NJ, Pollack IF. Jakacki RI, et al. Pediatr Blood Cancer. 2015 May;62(5):776-83. doi: 10.1002/pbc.25405. Epub 2015 Feb 19. Pediatr Blood Cancer. 2015. PMID: 25704363 Free PMC article. Clinical Trial.
• A patient tumor-derived orthotopic xenograft mouse model replicating the group 3 supratentorial primitive neuroectodermal tumor in children.
  Liu Z, Zhao X, Wang Y, Mao H, Huang Y, Kogiso M, Qi L, Baxter PA, Man TK, Adesina A, Su JM, Picard D, Ching Ho K, Huang A, Perlaky L, Lau CC, Chintagumpala M, Li XN. Liu Z, et al. Neuro Oncol. 2014 Jun;16(6):787-99. doi: 10.1093/neuonc/not244. Epub 2014 Jan 26. Neuro Oncol. 2014. PMID: 24470556 Free PMC article.
• p53 Restoration in Induction and Maintenance of Senescence: Differential Effects in Premalignant and Malignant Tumor Cells.
  Harajly M, Zalzali H, Nawaz Z, Ghayad SE, Ghamloush F, Basma H, Zainedin S, Rabeh W, Jabbour M, Tawil A, Badro DA, Evan GI, Saab R. Harajly M, et al. Mol Cell Biol. 2015 Nov 23;36(3):438-51. doi: 10.1128/MCB.00747-15. Print 2016 Feb 1. Mol Cell Biol. 2015. PMID: 26598601 Free PMC article.

References

1. 1. Eur J Cancer. 2006 May;42(8):1120-8 - PubMed
2. 1. Childs Nerv Syst. 1999 Oct;15(10):586-91 - PubMed
3. 1. Brain Pathol. 1997 Apr;7(2):765-84 - PubMed
4. 1. J Clin Oncol. 1995 Jul;13(7):1687-96 - PubMed
5. 1. J Clin Oncol. 1995 Jun;13(6):1377-83 - PubMed

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Medical

  • MedlinePlus Consumer Health Information
  • MedlinePlus Health Information